Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis

This study examined patient outcomes using real world data for acute myeloid leukemia (AML) patients initiating treatment. A retrospective, administrative claims-based, comparative analysis was developed to study outcomes for AML patients initiating treatment with decitabine or azacitidine between J...

Full description

Saved in:
Bibliographic Details
Published in:Experimental hematology & oncology 2014-03, Vol.3 (1), p.10-10, Article 10
Main Authors: Smith, B Douglas, Beach, Charles L, Mahmoud, Dalia, Weber, Laura, Henk, Henry J
Format: Article
Language:English
Subjects:
Cancer
Comparative analysis
Oncology, Experimental
Pharmaceutical industry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study examined patient outcomes using real world data for acute myeloid leukemia (AML) patients initiating treatment. A retrospective, administrative claims-based, comparative analysis was developed to study outcomes for AML patients initiating treatment with decitabine or azacitidine between January 2006 and June 2012. Treatment with azacitidine was associated with a longer median overall survival (10.1 versus 6.9 mos., p = 0.007) and a lower risk of hospitalization (HR 0.787, p = 0.02) compared to treatment with decitabine. This analysis of the outcomes of real-world treatment of AML patients with demethylating agents suggests that azacitidine may result in clinically superior outcomes than decitabine.
ISSN:2162-3619
2162-3619
DOI:10.1186/2162-3619-3-10